Current Heart Failure Reports

, Volume 14, Issue 6, pp 478–488 | Cite as

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure

  • Anett H. Ottesen
  • Geir Christensen
  • Torbjørn Omland
  • Helge Røsjø
Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors


Purpose of Review

Endocrine and paracrine factors influence the cardiovascular system and the heart by a number of different mechanisms. The chromogranin-secretogranin (granin) proteins seem to represent a new family of proteins that exerts both direct and indirect effects on cardiac and vascular functions. The granin proteins are produced in multiple tissues, including cardiac cells, and circulating granin protein concentrations provide incremental prognostic information to established risk indices in patients with myocardial dysfunction. In this review, we provide recent data for the granin proteins in relation with cardiovascular disease, and with a special focus on chromogranin A and heart failure.

Recent Findings

Chromogranin A is the most studied member of the granin protein family, and shorter, functionally active peptide fragments of chromogranin A exert protective effects on myocardial cell death, ischemia-reperfusion injury, and cardiomyocyte Ca2+ handling. Granin peptides have also been found to induce angiogenesis and vasculogenesis. Protein glycosylation is an important post-translational regulatory mechanism, and we recently found chromogranin A molecules to be hyperglycosylated in the failing myocardium. Chromogranin A hyperglycosylation impaired processing of full-length chromogranin A molecules into physiologically active chromogranin A peptides, and patients with acute heart failure and low rate of chromogranin A processing had increased mortality compared to other acute heart failure patients. Other studies have also demonstrated that circulating granin protein concentrations increase in parallel with heart failure disease stage.


The granin protein family seems to influence heart failure pathophysiology, and chromogranin A hyperglycosylation could directly be implicated in heart failure disease progression.


Chromogranin A Glycosylation Secretoneurin Cardiovascular disease Heart failure 



Work by the authors relating to granin proteins in cardiovascular disease have been funded by the Research Council of Norway, South-Eastern Regional Health Authority, Akershus University Hospital, Norwegian Health Association, the Anders Jahre Trust, Center for Heart Failure Research, University of Oslo, South-Eastern Norway Regional Health Authority, K.G. Jebsen Family Foundation, the Raagholt Trust, the Blix Trust, and the Odd Fellow Foundation.

Compliance with Ethical Standards

Conflicts of Interest

Anett H. Ottesen has received personal fees from CardiNor AS. TO has received research grants via Akershus University Hospital from Abbott Diagnostics, Roche Diagnostics, Singulex and AstraZeneca, and personal fees from Roche Diagnostics, Abbott Diagnostics, Bayer, Novartis, and CardiNor AS. HR has received personal fees from Novartis and CardiNor AS and research grants from Thermo Fisher BRAHMS, EuroDiagnostica, and Biomedica.

Helge Røsjø, Geir Christensen, and Torbjørn Omland are partners in a patent filed by the University of Oslo regarding the use of secretoneurin as a biomarker in patients with cardiovascular disease and patients with critical illness. HR, GC, and TO also have financial interests in CardiNor AS, which holds the license to commercialize secretoneurin.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted in bold and as: • Of importance

  1. 1.
    Ponikowski P, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2016. 2016;18(8):891–975.CrossRefGoogle Scholar
  2. 2.
    Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med. 2008;36(1 Suppl):S17–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Semenov AG, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009;55(3):489–98.PubMedCrossRefGoogle Scholar
  5. 5.
    Lunde IG, et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics. 2012;44(2):162–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Sanada S, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–49.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Kempf T, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17(5):581–8.PubMedCrossRefGoogle Scholar
  8. 8.
    • Bartolomucci A, et al. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32(6):755–97. Comprehensive review of the granin protein family PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci. 1991;16(1):27–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Røsjø H, et al. Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties. PLoS One. 2012;7(5):e37401.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Eskeland NL, et al. Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest. 1996;98(1):148–56.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Biswas N, et al. Proteolytic cleavage of human chromogranin A containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology. 2008;149(2):749–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang Q, et al. Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem. 2001;276(27):25022–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Biswas N, et al. Cathepsin L colocalizes with chromogranin A in chromaffin vesicles to generate active peptides. Endocrinology. 2009;150(8):3547–57.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Helle KB. Comparative studies on the soluble protein fractions of bovine, equine, porcine and ovine adrenal chromaffin granules. Biochem J. 1966;100(1):6C–7C.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    O'Connor DT. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept. 1983;6(3):263–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348(12):1134–49.PubMedCrossRefGoogle Scholar
  18. 18.
    Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992;49(3):497–528.PubMedCrossRefGoogle Scholar
  19. 19.
    • Pieroni M, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28(9):1117–27. First study to demonstrate increased myocardial CgA production in heart failure PubMedCrossRefGoogle Scholar
  20. 20.
    Biswas N, et al. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364–384)). Cell Tissue Res. 2010;342(3):353–61.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Røsjø H, et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail. 2010;12(6):549–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Rosa P, et al. The major tyrosine-sulfated protein of the bovine anterior pituitary is a secretory protein present in gonadotrophs, thyrotrophs, mammotrophs, and corticotrophs. J Cell Biol. 1985;100(3):928–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer-Colbrie R, Hagn C, Schober M. Chromogranins A, B, and C: widespread constituents of secretory vesicles. Ann N Y Acad Sci. 1987;493:120–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Heidrich FM, et al. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes. Circ Res. 2008;102(10):1230–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bergh J, et al. The release of chromogranin A and B like activity from human lung cancer cell lines. A potential marker for a subset of small cell lung cancer. Acta Oncol. 1989;28(5):651–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Sobol RE, et al. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med. 1986;105(5):698–700.PubMedCrossRefGoogle Scholar
  27. 27.
    Angelsen A, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30(1):1–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Angelsen A, et al. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate. 1997;31(2):110–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Paco S, et al. Regulation of exocytotic protein expression and Ca2+-dependent peptide secretion in astrocytes. J Neurochem. 2009;110(1):143–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Troger J, et al. Release of secretoneurin and noradrenaline from hypothalamic slices and its differential inhibition by calcium channel blockers. Naunyn Schmiedebergs Arch Pharmacol. 1994;349(6):565–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Mahata SK, et al. Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs. Ann N Y Acad Sci. 2002;971:27–38.PubMedCrossRefGoogle Scholar
  32. 32.
    Steiner HJ, et al. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem. 1990;38(6):845–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Yoo SH, et al. Coupling of the inositol 1,4,5-trisphosphate receptor and chromogranins A and B in secretory granules. J Biol Chem. 2000;275(17):12553–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Yoo SH. Secretory granules in inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells. FASEB J. 2010;24(3):653–64.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Yoo SH, Huh YH, Hur YS. Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins. Cell Mol Neurobiol. 2010;30(8):1155–61.PubMedCrossRefGoogle Scholar
  36. 36.
    Yoo SH, Hur YS. Enrichment of the inositol 1,4,5-trisphosphate receptor/Ca2+ channels in secretory granules and essential roles of chromogranins. Cell Calcium. 2012;51(3-4):342–50.PubMedCrossRefGoogle Scholar
  37. 37.
    • Mahapatra NR, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005;115(7):1942–52. First study to demonstrate that CHGA-/- mice develop a heart failure phenotype PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Mahata SK, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100(6):1623–33.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Angelone T, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology. 2008;149(10):4780–93.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Theurl M, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010;107(11):1326–35.PubMedCrossRefGoogle Scholar
  41. 41.
    O'Connor DT, et al. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002;20(7):1335–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Rao F, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115(17):2271–81.PubMedCrossRefGoogle Scholar
  43. 43.
    O'Connor DT, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005;90(9):5414–25.PubMedCrossRefGoogle Scholar
  44. 44.
    Fung MM, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens. 2010;32(5):278–87.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Egger M, et al. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol. 2008;598(1-3):104–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhang D, et al. Two chromogranin A-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS One. 2009;4(2):e4501.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept. 1992;41(1):9–18.PubMedCrossRefGoogle Scholar
  48. 48.
    • Ottesen AH, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. 2015;65(4):339–51. First study to demonstrate a direct link between granin peptides and cardiomyocyte Ca2+ handling PubMedCrossRefGoogle Scholar
  49. 49.
    Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51(4):468–73.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Angelone T, et al. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol. 2012;302(2):H431–42.PubMedCrossRefGoogle Scholar
  51. 51.
    • Ottesen AH, et al. Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis. Circ Heart Fail. 2017. 10(2). First study to report myocardial CgA hyperglycosylation in heart failure and that this may influence disease progression Google Scholar
  52. 52.
    Rosjo H, et al. Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. Circ Heart Fail. 2010;3(4):503–11.PubMedCrossRefGoogle Scholar
  53. 53.
    • Ceconi C, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23(12):967–74. First study to demonstrate increased circulating CgA concentrations in parallel with heart failure severity and the potential of CgA as a cardiac biomarker PubMedCrossRefGoogle Scholar
  54. 54.
    Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114(1):25–30.PubMedCrossRefGoogle Scholar
  55. 55.
    Estensen ME, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152(5):927. e1-6PubMedCrossRefGoogle Scholar
  56. 56.
    Jansson AM, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2009;30(1):25–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Røsjø H, et al. Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med. 2012;38(5):820–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Zhang D, et al. Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem. 2008;54(9):1497–503.PubMedCrossRefGoogle Scholar
  59. 59.
    Lu L, et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease. Eur Heart J. 2012;33(18):2297–306.PubMedCrossRefGoogle Scholar
  60. 60.
    Zhu D, et al. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers. 2011;16(8):691–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Goetze JP, et al. Making sense of chromogranin A in heart disease. Lancet Diabetes Endocrinol. 2013;1(1):7–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Myhre PL, et al. Circulating chromogranin B levels in patients with acute respiratory failure: data from the FINNALI Study. Biomarkers. 2017: 1–7.Google Scholar
  63. 63.
    Leitner B, et al. Secretogranin II: relative amounts and processing to secretoneurin in various rat tissues. J Neurochem. 1996;66(3):1312–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Røsjø H, et al. Prognostic value of secretoneurin in critically ill patients with infections. Crit Care Med. 2016;44(10):1882–90.PubMedCrossRefGoogle Scholar
  65. 65.
    Myhre PL, et al. Prognostic value of secretoneurin in patients with acute respiratory failure: data from the FINNALI Study. Clin Chem. 2016;62(10):1380–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Hasslacher J, et al. Secretoneurin as a marker for hypoxic brain injury after cardiopulmonary resuscitation. Intensive Care Med. 2014;40(10):1518–27.PubMedCrossRefGoogle Scholar
  67. 67.
    Røsjø H, et al. Effect of short- and long-term physical activities on circulating granin protein levels. Regul Pept. 2013;185:14–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Bauer SH, et al. Chromogranin A from bovine adrenal medulla: molecular characterization of glycosylations, phosphorylations, and sequence heterogeneities by mass spectrometry. Anal Biochem. 1999;274(1):69–80.PubMedCrossRefGoogle Scholar
  69. 69.
    O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314(18):1145–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Pasqua T, et al. Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology. 2013;154(9):3353–65.PubMedCrossRefGoogle Scholar
  71. 71.
    Røsjø H, et al. Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. Clin Chem. 2015;61(8):1087–97.PubMedCrossRefGoogle Scholar
  72. 72.
    Jiang J, et al. Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. Clin Chem. 2010;56(6):959–66.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Kennedy BP, et al. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides. 1998;19(7):1241–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Mazza R, et al. Catestatin (chromogranin A344–364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol. 2008;295(1):H113–22.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Gayen JR, et al. Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology. 2009;150(11):5027–35.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Dev NB, et al. Chromogranin A and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology. 2010;151(6):2760–8.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Imbrogno S, et al. The catecholamine release-inhibitory peptide catestatin (chromogranin A344–363) modulates myocardial function in fish. J Exp Biol. 2010;213(Pt 21):3636–43.Google Scholar
  78. 78.
    Penna C, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol. 2010;30(8):1171–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Bassino E, et al. Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K-Akt-GSK3beta pathway and preserving mitochondrial membrane potential. PLoS One. 2015;10(3):e0119790.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Angelone T, Mazza R, Cerra MC. Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem. 2012;19(24):4042–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Perrelli MG, et al. Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling. Pflugers Arch. 2013;465(7):1031–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Bassino E, et al. Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K-Akt-GSK3beta pathway and preserving mitochondrial membrane potential. PLoS One. 2015;10(3):e0119790.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Corti A, et al. Vasostatins exert negative inotropism in the working heart of the frog. Ann N Y Acad Sci. 2002;971:362–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Tota B, et al. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac beta-adrenergic-like inotropes. FASEB J. 2012;26(7):2888–98.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Cappello S, et al. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol. 2007;293(1):H719–27.PubMedCrossRefGoogle Scholar
  86. 86.
    Stavrakis S, et al. Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation. J Cardiovasc Electrophysiol. 2012;23(7):771–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Yu M, et al. Overexpression of vasostatin-1 protects hypoxia/reoxygenation injuries in cardiomyocytes independent of endothelial cells. Cardiovasc Ther. 2012;30(3):145–51.PubMedCrossRefGoogle Scholar
  88. 88.
    Salem S, et al. Identification of the vasoconstriction-inhibiting factor (VIF), a potent endogenous cofactor of angiotensin II acting on the angiotensin II type 2 receptor. Circulation. 2015;131(16):1426–34.PubMedCrossRefGoogle Scholar
  89. 89.
    Wang D, et al. Vasostatin-1 stops structural remodeling and improves calcium handling via the eNOS-NO-PKG pathway in rat hearts subjected to chronic beta-adrenergic receptor activation. Cardiovasc Drugs Ther. 2016;30(5):455–64.PubMedCrossRefGoogle Scholar
  90. 90.
    Filice, E., et al., Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury. Peptides, 2015. 71: p. 40-8.Google Scholar
  91. 91.
    Tota B, et al. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac beta-adrenergic-like inotropes. FASEB J. 2012;26(7):2888–98.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Schgoer W, et al. Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism. Circ Res. 2009;105(10):994–1002.PubMedCrossRefGoogle Scholar
  93. 93.
    Albrecht-Schgoer K, et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2012;126(21):2491–501.PubMedCrossRefGoogle Scholar
  94. 94.
    Schgoer W, et al. Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. PLoS One. 2013;8(9):e74029.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Theurl M, et al. Secretoneurin gene therapy improves hind limb and cardiac ischaemia in Apo E(-)/(-) mice without influencing systemic atherosclerosis. Cardiovasc Res. 2015;105(1):96–106.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Anett H. Ottesen
    • 1
    • 2
    • 3
  • Geir Christensen
    • 2
    • 3
  • Torbjørn Omland
    • 1
    • 2
  • Helge Røsjø
    • 1
    • 2
    • 4
  1. 1.Division of MedicineAkershus University HospitalLørenskogNorway
  2. 2.Center for Heart Failure ResearchUniversity of OsloOsloNorway
  3. 3.Institute for Experimental Medical ResearchOslo University HospitalUllevålNorway
  4. 4.University Hospital Uppsala and Uppsala Clinical Research CenterUppsalaSweden

Personalised recommendations